AAPL329.98-3.11 (-0.93%) ▼|ABBV263.34+1.57 (+0.60%) ▲|ABT102.00-1.09 (-1.06%) ▼|ACN195.83+0.83 (+0.43%) ▲|ADBE260.77-4.83 (-1.82%) ▼|AMAT419.81-4.40 (-1.04%) ▼|AMD503.78+10.37 (+2.10%) ▲|AMGN377.98-3.53 (-0.92%) ▼|AMT178.43+1.49 (+0.84%) ▲|AMZN249.01-4.53 (-1.79%) ▼|AVGO340.65-4.07 (-1.18%) ▼|AXP323.14-4.64 (-1.42%) ▼|BA209.13-1.14 (-0.54%) ▼|BAC59.12-0.36 (-0.60%) ▼|BKNG170.94-4.41 (-2.52%) ▼|BLK1,056.00-9.60 (-0.90%) ▼|BMY63.91-0.19 (-0.30%) ▼|BNY153.25-4.41 (-2.80%) ▼|BRK-B516.19+1.24 (+0.24%) ▲|C135.20-0.98 (-0.72%) ▼|CAT781.96-2.04 (-0.26%) ▼|CL87.09-0.80 (-0.91%) ▼|CMCSA24.61-0.28 (-1.11%) ▼|COF204.28-2.40 (-1.16%) ▼|COP140.20+3.53 (+2.58%) ▲|COST908.78-10.13 (-1.10%) ▼|CRM259.29-0.14 (-0.05%) ▼|CSCO110.80+0.74 (+0.67%) ▲|CVS94.42-1.13 (-1.18%) ▼|CVX216.31+4.14 (+1.95%) ▲|DE686.30+4.84 (+0.71%) ▲|DHR208.01+4.76 (+2.34%) ▲|DIS107.63-0.96 (-0.88%) ▼|DUK118.11-0.92 (-0.77%) ▼|EMR146.25-2.05 (-1.38%) ▼|FDX308.33-4.24 (-1.36%) ▼|GD357.50+0.69 (+0.19%) ▲|GE308.25-9.31 (-2.93%) ▼|GEV877.69+2.93 (+0.33%) ▲|GILD145.72+0.13 (+0.09%) ▲|GM85.61-1.55 (-1.78%) ▼|GOOG339.92-5.80 (-1.68%) ▼|GOOGL343.45-5.94 (-1.70%) ▼|GS960.99-27.46 (-2.78%) ▼|HD306.13-4.74 (-1.52%) ▼|HON201.19-0.19 (-0.09%) ▼|IBM248.70-0.39 (-0.16%) ▼|INTC98.30+1.11 (+1.14%) ▲|INTU331.73-7.42 (-2.19%) ▼|ISRG375.45-2.49 (-0.66%) ▼|JNJ264.91-1.41 (-0.53%) ▼|JPM344.99-5.15 (-1.47%) ▼|KO88.59-0.23 (-0.26%) ▼|LIN461.38-3.04 (-0.65%) ▼|LLY1,146.16+7.88 (+0.69%) ▲|LMT530.40+1.02 (+0.19%) ▲|LOW195.10-3.07 (-1.55%) ▼|LRCX267.88-5.61 (-2.05%) ▼|MA572.61-1.81 (-0.32%) ▼|MCD256.17-1.32 (-0.51%) ▼|MDLZ62.17-0.22 (-0.35%) ▼|MDT94.01+0.21 (+0.22%) ▲|META666.22+0.62 (+0.09%) ▲|MMM164.56+2.54 (+1.57%) ▲|MO70.18+0.68 (+0.97%) ▲|MRK143.79-0.21 (-0.15%) ▼|MS201.33-5.25 (-2.54%) ▼|MSFT499.27-6.14 (-1.21%) ▼|MU927.13+3.10 (+0.33%) ▲|NEE81.53-0.10 (-0.12%) ▼|NFLX78.00-2.33 (-2.89%) ▼|NKE36.40-0.65 (-1.75%) ▼|NOW144.72+2.37 (+1.66%) ▲|NVDA212.27+1.31 (+0.62%) ▲|ORCL143.54-1.25 (-0.86%) ▼|PEP135.68-0.66 (-0.48%) ▼|PFE27.57-0.15 (-0.54%) ▼|PG147.13+1.00 (+0.68%) ▲|PLTR172.46-0.86 (-0.49%) ▼|PM191.10-3.79 (-1.94%) ▼|QCOM187.87+7.72 (+4.29%) ▲|RTX194.00-1.34 (-0.69%) ▼|SBUX97.95-1.12 (-1.13%) ▼|SCHW107.86+0.55 (+0.51%) ▲|SO86.67-0.34 (-0.39%) ▼|SPG203.35-1.62 (-0.79%) ▼|T26.63+0.12 (+0.43%) ▲|TMO632.86+19.56 (+3.19%) ▲|TMUS183.12+0.22 (+0.12%) ▲|TSLA361.04+2.07 (+0.58%) ▲|TXN265.19+1.77 (+0.67%) ▲|UBER72.22-0.42 (-0.57%) ▼|UNH378.73-4.83 (-1.26%) ▼|UNP283.26-1.82 (-0.64%) ▼|UPS102.44-0.02 (-0.02%) ▼|USB62.95+0.27 (+0.42%) ▲|V374.57-0.72 (-0.19%) ▼|VZ51.29-0.01 (-0.01%) ▼|WFC91.14+2.43 (+2.74%) ▲|WMT108.52-0.56 (-0.51%) ▼|XOM167.23+2.17 (+1.31%) ▲|AAPL329.98-3.11 (-0.93%) ▼|ABBV263.34+1.57 (+0.60%) ▲|ABT102.00-1.09 (-1.06%) ▼|ACN195.83+0.83 (+0.43%) ▲|ADBE260.77-4.83 (-1.82%) ▼|AMAT419.81-4.40 (-1.04%) ▼|AMD503.78+10.37 (+2.10%) ▲|AMGN377.98-3.53 (-0.92%) ▼|AMT178.43+1.49 (+0.84%) ▲|AMZN249.01-4.53 (-1.79%) ▼|AVGO340.65-4.07 (-1.18%) ▼|AXP323.14-4.64 (-1.42%) ▼|BA209.13-1.14 (-0.54%) ▼|BAC59.12-0.36 (-0.60%) ▼|BKNG170.94-4.41 (-2.52%) ▼|BLK1,056.00-9.60 (-0.90%) ▼|BMY63.91-0.19 (-0.30%) ▼|BNY153.25-4.41 (-2.80%) ▼|BRK-B516.19+1.24 (+0.24%) ▲|C135.20-0.98 (-0.72%) ▼|CAT781.96-2.04 (-0.26%) ▼|CL87.09-0.80 (-0.91%) ▼|CMCSA24.61-0.28 (-1.11%) ▼|COF204.28-2.40 (-1.16%) ▼|COP140.20+3.53 (+2.58%) ▲|COST908.78-10.13 (-1.10%) ▼|CRM259.29-0.14 (-0.05%) ▼|CSCO110.80+0.74 (+0.67%) ▲|CVS94.42-1.13 (-1.18%) ▼|CVX216.31+4.14 (+1.95%) ▲|DE686.30+4.84 (+0.71%) ▲|DHR208.01+4.76 (+2.34%) ▲|DIS107.63-0.96 (-0.88%) ▼|DUK118.11-0.92 (-0.77%) ▼|EMR146.25-2.05 (-1.38%) ▼|FDX308.33-4.24 (-1.36%) ▼|GD357.50+0.69 (+0.19%) ▲|GE308.25-9.31 (-2.93%) ▼|GEV877.69+2.93 (+0.33%) ▲|GILD145.72+0.13 (+0.09%) ▲|GM85.61-1.55 (-1.78%) ▼|GOOG339.92-5.80 (-1.68%) ▼|GOOGL343.45-5.94 (-1.70%) ▼|GS960.99-27.46 (-2.78%) ▼|HD306.13-4.74 (-1.52%) ▼|HON201.19-0.19 (-0.09%) ▼|IBM248.70-0.39 (-0.16%) ▼|INTC98.30+1.11 (+1.14%) ▲|INTU331.73-7.42 (-2.19%) ▼|ISRG375.45-2.49 (-0.66%) ▼|JNJ264.91-1.41 (-0.53%) ▼|JPM344.99-5.15 (-1.47%) ▼|KO88.59-0.23 (-0.26%) ▼|LIN461.38-3.04 (-0.65%) ▼|LLY1,146.16+7.88 (+0.69%) ▲|LMT530.40+1.02 (+0.19%) ▲|LOW195.10-3.07 (-1.55%) ▼|LRCX267.88-5.61 (-2.05%) ▼|MA572.61-1.81 (-0.32%) ▼|MCD256.17-1.32 (-0.51%) ▼|MDLZ62.17-0.22 (-0.35%) ▼|MDT94.01+0.21 (+0.22%) ▲|META666.22+0.62 (+0.09%) ▲|MMM164.56+2.54 (+1.57%) ▲|MO70.18+0.68 (+0.97%) ▲|MRK143.79-0.21 (-0.15%) ▼|MS201.33-5.25 (-2.54%) ▼|MSFT499.27-6.14 (-1.21%) ▼|MU927.13+3.10 (+0.33%) ▲|NEE81.53-0.10 (-0.12%) ▼|NFLX78.00-2.33 (-2.89%) ▼|NKE36.40-0.65 (-1.75%) ▼|NOW144.72+2.37 (+1.66%) ▲|NVDA212.27+1.31 (+0.62%) ▲|ORCL143.54-1.25 (-0.86%) ▼|PEP135.68-0.66 (-0.48%) ▼|PFE27.57-0.15 (-0.54%) ▼|PG147.13+1.00 (+0.68%) ▲|PLTR172.46-0.86 (-0.49%) ▼|PM191.10-3.79 (-1.94%) ▼|QCOM187.87+7.72 (+4.29%) ▲|RTX194.00-1.34 (-0.69%) ▼|SBUX97.95-1.12 (-1.13%) ▼|SCHW107.86+0.55 (+0.51%) ▲|SO86.67-0.34 (-0.39%) ▼|SPG203.35-1.62 (-0.79%) ▼|T26.63+0.12 (+0.43%) ▲|TMO632.86+19.56 (+3.19%) ▲|TMUS183.12+0.22 (+0.12%) ▲|TSLA361.04+2.07 (+0.58%) ▲|TXN265.19+1.77 (+0.67%) ▲|UBER72.22-0.42 (-0.57%) ▼|UNH378.73-4.83 (-1.26%) ▼|UNP283.26-1.82 (-0.64%) ▼|UPS102.44-0.02 (-0.02%) ▼|USB62.95+0.27 (+0.42%) ▲|V374.57-0.72 (-0.19%) ▼|VZ51.29-0.01 (-0.01%) ▼|WFC91.14+2.43 (+2.74%) ▲|WMT108.52-0.56 (-0.51%) ▼|XOM167.23+2.17 (+1.31%) ▲|
20.3 C
New York
Tuesday, September 15, 2026

Tag: management

Once-Weekly Insulin Efsitora Achieves Comparable A1C Reduction to Daily Insulin Therapy

Once-weekly insulin helped patients achieve an average A1C of 6.92% in QWINT-1 trial Results support once-weekly insulin as effective alternative to daily treatment CHICAGO, June 22,...

INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Red Cat Holdings, Inc. (RCAT) Investors with Substantial Losses Have Opportunity to Lead Investor...

SAN DIEGO, June 22, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Red Cat Holdings, Inc. (NASDAQ: RCAT) securities between March 18, 2022 and January 15, 2025, inclusive (the “Class Period”), have until Tuesday, July 22, 2025 to seek appointment as lead plaintiff of the Red Cat class action lawsuit. Captioned Olsen v. Red Cat Holdings, Inc., No. 25-cv-05427 (D.N.J.), the Red Cat class action lawsuit charges Red Cat as well as certain of Red Cat’s top current and former executives with violations of the Securities Exchange Act of 1934.

FinThrive Introduces Agentic AI at HFMA 2025 to Help Customers Transform Healthcare Revenue Cycle Management Performance

Company to also highlight advancements in denials and underpayments management and speak to the measurable impact of RCM technology adoption DENVER, June 22, 2025 /PRNewswire/...

Cyberway Product Innovation Platform: Empowering Enterprise Innovation Processes and Building Exceptional Product Strength

GUANGZHOU , June 22, 2025 /PRNewswire/ -- In the fiercely competitive FMCG market, only efficient innovation can create a true competitive edge. As consumer preferences...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 3D Systems Corporation – DDD

NEW YORK, June 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  3D Systems Corporation ("3D Systems" or the...

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published...

Bagsværd, Denmark, 22 June – Today, The New England Journal of Medicine (NEJM) published results from Novo Nordisk’s phase 3 REDEFINE 1 trial evaluating the efficacy and safety of investigational CagriSema plus lifestyle interventions for weight loss in adults with obesity or overweight who have a weight-related medical complication and without diabetes.1 REDEFINE 1 met its co-primary endpoints and achieved statistically significant and clinically meaningful weight loss at 68 weeks in patients taking CagriSema versus placebo.1 These data, along with the related phase 3 REDEFINE 2 study conducted in adults with overweight or obesity and type 2 diabetes, were presented today during a scientific symposium at the American Diabetes Association’s (ADA) 85th Scientific Sessions and published in NEJM.

CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM

Data presented simultaneously at the American Diabetes Association's® 85th Scientific Sessions, showed mean weight reduction in the highest range of efficacy observed with existing...

CagriSema Demonstrates Significant Weight Loss in Adults with Obesity

Once-weekly medication results in weight loss of up to 22.7% in adults without diabetes and 15.7% in those with type 2 diabetes CHICAGO, June 22,...

FinThrive Debuts Denials and Underpayments Analyzer, a Unified Solution for Denials and Underpayments, at HFMA 2025

Next generation analyzer helps hospitals protect revenue before it's lost by delivering timely end-to-end visibility and actionable intelligence DENVER, June 22, 2025 /PRNewswire/ --...

Analyzing U.S. Household Electricity Price Increases—Strategic Implications for Stakeholders

Electricity prices are escalating rapidly for U.S. households, despite a general cooling in overall inflation. The consumer price index for May 2025 indicated a...

Tariffs Impact Small Business—Strategies for Mitigating Financial Risk

President Trump's tariff policies have created significant volatility, impacting various sectors, with small businesses bearing the brunt. Yair Reiner, an entrepreneur, discusses on "The...

SK Group and AWS Team Up to Build Cloud Computing Infrastructure to Support AI Innovation

SK Group, in partnership with AWS, will provide data center infrastructure for a new AWS AI Zone location in Ulsan that will support AI...

Unlock Your Wealth: Discover the AI Stock Gem Bouncing Back for Savvy Women Investors

Hey, fabulous ladies! 💁‍♀️ Who's ready to chat about making those dollars work smarter, not harder? Today, we're diving into the world of AI...

Abvance Therapeutics Announces Presentation of Human Clinical Data at the 85th Scientific Sessions of the American Diabetes Association

Abvance presents first-in-human data on insulin-glucagon co-dosing in T1D, demonstrating a novel approach to help prevent hypoglycemia

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsManagement